Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.

Zanchin, Christian; Yamaji, Kyohei; Rogge, Carolin; Lesche, Dorothea; Zanchin, Thomas; Ueki, Yasushi; Windecker, Stephan; Mohacsi, Paul; Räber, Lorenz; Sigurdardottir, Vilborg (2018). Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography. PLoS ONE, 13(8), e0202950. Public Library of Science 10.1371/journal.pone.0202950

Preview

Text Progression of cardiac allograft vasculopathy .pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (6MB) | Preview

BACKGROUND

The purpose of the present study was to assess the short- and long-term progression of cardiac allograft vasculopathy (CAV) using serial 3-vessel quantitative coronary angiography (QCA).

METHODS

CAV progression was assessed using serial 3-vessel QCA analysis at baseline, 1-year and long-term angiographic follow-up (8.5±3.7 years) after heart transplantation. The change in minimal lumen diameter (MLD) and percent diameter stenosis (%DS) was serially assessed within matched segments. Patients were graded according to the ISHLT-CAV classification and grouped as ISHLT-CAV0 and ISHLT-CAV1-3. The primary endpoint was mean change in MLD and %DS.

RESULTS

A total of 41 patients and 520 matched segments were available for serial 3-vessel QCA. Overall, MLD decreased non-significantly from baseline to 1-year follow-up and significantly from 1-year to the long-term angiographic follow-up (Δ-0.08mm/year [95%CI -0.11 to -0.05], P<0.001). %DS increased significantly from baseline to 1-year (Δ+0.96%/year [95%CI 0.04 to 1.88], P = 0.041) and from 1-year to long-term angiographic follow-up (Δ+0.61%/year [95%CI 0.33 to 0.88], P<0.001). ISHLT-CAV1-3 at 1 year and at long-term angiographic follow-up was observed in 22% and 61%, respectively. Between baseline and long-term angiographic follow-up, a significant reduction in MLD was observed within both groups without a significant difference in the reduction between the two groups (ISHLT-CAV0: median -0.49mm [IQR -0.54 to -0.43] vs. ISHLT-CAV1-3: median -0.40mm [IQR -0.44 to -0.35], P = 0.4).

CONCLUSION

The current data suggest that QCA can't predict CAV beyond 1 year, but, QCA affirmed that CAV progresses to a similar extent in patients who do not develop visual CAV during long-term follow-up.

Interest & Impact

Downloads

125 since deposited on 05 Feb 2019
21 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item